Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Colorectal Neoplasms 22Squamous Cell Carcinoma of Head and Neck 13Carcinoma, Non-Small-Cell Lung 12Neoplasms 6Rectal Neoplasms 5Neoplasm Metastasis 5Mouth Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Colonic Neoplasms 5Pancreatic Neoplasms 4Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma 3Thyroid Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Endometrial Neoplasms 2Urologic Neoplasms 1Solid Tumors 1Soft Tissue Neoplasms 1Skin Neoplasms 1Sarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1Neurofibromatosis 1 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 7Cisplatin 6pembrolizumab 4durvalumab 4Platinum 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4cemiplimab 3Radiation 3Paclitaxel 3Cetuximab 3Biopsy 3(225)Ac-DOTA-c(RGDyK) 3cabozantinib 2atezolizumab 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Pemetrexed 2Nivolumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2ALT-803 2130-nm albumin-bound paclitaxel 2zipalertinib 1repotrectinib 1poly ICLC 1ipatasertib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma × Cetuximab × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06589804 2026-06-03

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

National Cancer Institute (NCI)

Phase 3 Recruiting
158 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡